CVRX INC (CVRX)
Health Care · NASDAQ
CVRx commercializes Barostim, the first FDA-approved neuromodulation device that activates baroreceptors to treat severe heart failure in patients who fail traditional medications.
What CVRX INC does
CVRx is a commercial-stage medical device company developing and commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to baroreceptors in the carotid artery to treat heart failure with reduced ejection fraction (HFrEF). The device uses Baroreflex Activation Therapy (BAT) to modulate the autonomic nervous system and improve cardiovascular function in patients who have failed medical therapy. Barostim is FDA-approved in the U.S. and CE-marked in Europe, and the company is building a dedicated sales force and securing reimbursement coverage to drive adoption in hospitals and outpatient centers.
Themes: ["neuromodulation / cardiac","heart failure treatment","HFrEF / reduced ejection fraction","implantable medical devices","cardiovascular autonomic regulation","refractory hypertension indication"]
Fundamentals
- Price$5.20 as of 2026-07-09 close
- Market cap$138M as of 2026-07-10
- 1-year return-21.9% as of 2026-07-09 close
- Net margin-89.2% as of 2026-07-10
- Gross margin+86.2% as of 2026-07-10
- ROE-120.8% as of 2026-07-10
- Debt / equity2.01 as of 2026-07-10
- Revenue growth (YoY)+11.7% as of 2026-07-10
- Revenue CAGR (3y)+36.1% SEC XBRL
- Beta0.80 as of 2026-07-10
Key risks (from latest filing)
["Commercialization execution risk: company expects to incur net losses for several years as it scales sales force and physician training while building market awareness and reimbursement coverage","Reimbursement dependency: 67% of target patients are Medicare-eligible; company relies on CMS coverage and prior authorization processes from multiple payers; loss of reimbursement coverage or unfavorable payment rates would significantly impact adoption","Supply chain concentration: multiple Barostim components sourced from limited suppliers with significant lead times; supply interruptions could constrain manufacturing and revenue growth"]
Competitors & peers
- Abbott (ABT)
- Boston Scientific (BSX)
- Medtronic (MDT)
- LivaNova (LVNA)
- Cardiac neuromodulation devices
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.